Mary L. Morris

1.1k total citations
15 papers, 860 citations indexed

About

Mary L. Morris is a scholar working on Epidemiology, Immunology and Hepatology. According to data from OpenAlex, Mary L. Morris has authored 15 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 4 papers in Immunology and 3 papers in Hepatology. Recurrent topics in Mary L. Morris's work include Immune Response and Inflammation (4 papers), Hepatitis B Virus Studies (4 papers) and Immunotherapy and Immune Responses (3 papers). Mary L. Morris is often cited by papers focused on Immune Response and Inflammation (4 papers), Hepatitis B Virus Studies (4 papers) and Immunotherapy and Immune Responses (3 papers). Mary L. Morris collaborates with scholars based in United States, Canada and Switzerland. Mary L. Morris's co-authors include Heather L. Davis, D. William Cameron, Curtis Cooper, A M Krieg, Susan M. Efler, Jenny Heathcote, Isabelle Seguin, John B. Stanbury, Jonathan B. Angel and Arthur Μ. Krieg and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Clinical Endocrinology & Metabolism and Endocrinology.

In The Last Decade

Mary L. Morris

15 papers receiving 790 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary L. Morris United States 9 515 308 227 124 97 15 860
Martine Baudin France 13 256 0.5× 394 1.3× 126 0.6× 75 0.6× 70 0.7× 25 750
Enrico Schiaffella Italy 12 353 0.7× 171 0.6× 113 0.5× 192 1.5× 56 0.6× 15 657
Mimi Guebre‐Xabier United States 15 335 0.7× 279 0.9× 182 0.8× 277 2.2× 22 0.2× 24 858
Ana C. Tuyama United States 11 116 0.2× 390 1.3× 70 0.3× 100 0.8× 233 2.4× 13 622
M. Ohuchi Japan 17 143 0.3× 581 1.9× 226 1.0× 184 1.5× 27 0.3× 24 959
Irene S. Ludwig Netherlands 17 459 0.9× 139 0.5× 258 1.1× 126 1.0× 44 0.5× 33 810
Virginia Takahashi United States 11 162 0.3× 185 0.6× 147 0.6× 132 1.1× 91 0.9× 15 503
Timothy J. Holzer United States 12 251 0.5× 366 1.2× 140 0.6× 235 1.9× 20 0.2× 23 716
Donald R. Skillman United States 14 230 0.4× 202 0.7× 97 0.4× 268 2.2× 49 0.5× 17 796
Bertrand Georges France 12 259 0.5× 240 0.8× 172 0.8× 110 0.9× 26 0.3× 26 529

Countries citing papers authored by Mary L. Morris

Since Specialization
Citations

This map shows the geographic impact of Mary L. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary L. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary L. Morris more than expected).

Fields of papers citing papers by Mary L. Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary L. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary L. Morris. The network helps show where Mary L. Morris may publish in the future.

Co-authorship network of co-authors of Mary L. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Mary L. Morris. A scholar is included among the top collaborators of Mary L. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary L. Morris. Mary L. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
McHutchison, John G., Paul Y. Kwo, B. Freilich, et al.. (2006). 730 Early viral response to CPG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. Journal of Hepatology. 44. S269–S269. 13 indexed citations
2.
McHutchison, John G., Bruce R. Bacon, Stuart C. Gordon, et al.. (2006). 111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus. Journal of Hepatology. 44. S49–S49. 7 indexed citations
3.
Cooper, Curtis, Heather L. Davis, Jonathan B. Angel, et al.. (2005). CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 19(14). 1473–1479. 162 indexed citations
4.
Siegrist, Claire‐Anne, Maria Pihlgren, Chantal Tougne, et al.. (2004). Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine. 23(5). 615–622. 91 indexed citations
5.
Cooper, Curtis, Heather L. Davis, Mary L. Morris, et al.. (2004). CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B� HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study. Journal of Clinical Immunology. 24(6). 693–701. 270 indexed citations
6.
Cooper, Curtis, Heather L. Davis, Mary L. Morris, et al.. (2004). Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 22(23-24). 3136–3143. 209 indexed citations
7.
Morris, Mary L., et al.. (2000). SHORT REPORT. Australasian Journal of Environmental Management. 7(1). 6–10. 1 indexed citations
8.
Heathcote, Jenny, et al.. (2000). CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine Preliminary results of phase I trial with CpG ODN 7909. 2. 378. 14 indexed citations
9.
Warn‐Varnas, A., et al.. (1983). Studies of large-scale thermal variability with a synoptic mixed-layer model. AIP conference proceedings. 106. 515–536. 2 indexed citations
10.
11.
12.
Meschan, I., et al.. (1966). The quantitation of the Renografin-iodine-131 renogram for renal clearance determination.. PubMed. 7(6). 442–53. 3 indexed citations
13.
Stanbury, John B., et al.. (1960). THYROXINE DEIODINATION BY A MICROSOMAL PREPARATION REQUIRING FE++, OXYGEN, AND CYSTEINE OR GLUTATHIONE1. Endocrinology. 67(3). 353–362. 16 indexed citations
14.
Stanbury, John B. & Mary L. Morris. (1958). Deiodination of Diiodotyrosine by Cell-Free Systems. Journal of Biological Chemistry. 233(1). 106–108. 50 indexed citations
15.
Stanbury, John B. & Mary L. Morris. (1957). THE METABOLISM OF 3:3'-DIIODOTHYRONINE IN MAN*. The Journal of Clinical Endocrinology & Metabolism. 17(11). 1324–1331. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martine Baudin Breakdown of academic impact, for papers by Enrico Schiaffella Breakdown of academic impact, for papers by Mimi Guebre‐Xabier Breakdown of academic impact, for papers by Ana C. Tuyama Breakdown of academic impact, for papers by M. Ohuchi Breakdown of academic impact, for papers by Irene S. Ludwig Breakdown of academic impact, for papers by Virginia Takahashi Breakdown of academic impact, for papers by Timothy J. Holzer Breakdown of academic impact, for papers by Donald R. Skillman Breakdown of academic impact, for papers by Bertrand Georges
Rankless by CCL
2026